Lansoprazole (Prevacid)

A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Also Known As:

Prevacid; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; AG 1749; AG-1749; Agopton; Bamalite; Lansol; Lansoprazol; Lansoprazole Sodium; Lanzor; Monolitum; Ogast; Ogastro; Opiren; Prezal; Pro Ulco; Promeco; Takepron; Ulpax; Zoton; AG1749; Sodium, Lansoprazole; Lansoprazoles

Networked: 1041 relevant articles (192 outcomes, 246 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kinoshita, Yoshikazu: 9 articles (06/2016 - 02/2003)
2.	Huang, Bidan: 9 articles (01/2007 - 01/2002)
3.	Peura, David A: 8 articles (08/2011 - 06/2004)
4.	Lima, John J: 7 articles (01/2019 - 01/2012)
5.	Ashida, Kiyoshi: 7 articles (04/2018 - 01/2008)
6.	Sugano, Kentaro: 7 articles (01/2018 - 06/2011)
7.	Atkinson, Stuart: 7 articles (05/2010 - 01/2008)
8.	Takagi, Tomohisa: 6 articles (05/2022 - 10/2004)
9.	Fais, Stefano: 6 articles (08/2016 - 12/2011)
10.	Holbrook, Janet T: 6 articles (07/2015 - 01/2012)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 01/01/2010 - "Results of multicenter study "Efficacy of Lansoptol (lansoprazole, KRKA) and its influence on the Dynamics of GERD symptoms" (LIEDER) are presented. " 12/01/2005 - "Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients." 01/01/2002 - "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age. " 01/01/2002 - "Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children." 05/01/1994 - "The pharmacokinetics, pharmacodynamics and clinical safety of lansoprazole are discussed elsewhere in this supplement, and so this review will focus upon the European and American experience of the efficacy of lansoprazole in the treatment of peptic ulceration and gastro-oesophageal reflux."
2.	Duodenal Ulcer (Curling's Ulcer) 10/01/1996 - "Lansoprazole was effective for prompt symptom relief in most patients and was able to heal more than 90% of gastric and duodenal ulcers with minimal side effects." 10/01/1995 - "Lansoprazole is an effective and safe treatment for duodenal ulcer and the 15 mg dose is as effective as 30 or 60 mg." 09/01/1995 - "It is shown that lansoprazole is effective and safe for treatment of duodenal ulcer." 01/01/2023 - "This study aimed to establish the noninferiority of keverprazan to lansoprazole in the treatment of patients with duodenal ulcer (DU). " 12/01/1997 - "This randomized, double-blind, placebo-controlled study assessed the value of treatment with low-dose lansoprazole in preventing duodenal ulcer recurrence. "
3.	Ulcer 01/01/1991 - "AG-1749 raised the percentage of time with high pH to 99% from the 68% obtained with an H2RA and cured 88% of this type of ulcer. " 10/15/2003 - "Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial." 07/01/1999 - "Within 1 month of study initiation, 27% (four out of 15) of placebo-treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. " 01/01/1995 - "In study II, the ulcer contraction rate after 8 weeks of treatment with lansoprazole was 71.8%, significantly higher than that achieved with H2-receptor antagonists. " 01/01/1995 - "The effect of lansoprazole versus an H2-receptor antagonist on the contraction of ulcer echoes (study II) was also investigated. "
4.	Heartburn (Pyrosis) 09/01/2009 - "Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. " 09/01/2009 - "Percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1 were significantly greater with lansoprazole 15 or 30 mg vs. placebo. " 09/01/2009 - "Endpoints were percentage of night times without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Mean percentage of night times without heartburn was significantly greater with lansoprazole 15 mg (61.3%) or lansoprazole 30 mg (61.7%) vs. placebo (47.8%) over 14 days (P < 0.0001 vs. placebo for both doses). " 07/01/2009 - "Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies." 04/01/2014 - "After 4 weeks of lansoprazole treatment, heartburn symptoms were improved in 75.7 % of patients and symptoms of postprandial fullness were improved in 68.7 % of patients. "
5.	Infections 08/01/2001 - "pylori infection, compared with a lansoprazole-based regimen, in a randomized multicentre study. " 07/01/2000 - "pylori infection, compared with that based on lansoprazole, in a randomized multicentre study. " 04/01/2001 - "Patients with active Helicobacter pylori infection underwent a baseline 14C-UBT (UBT-1) followed by treatment with lansoprazole 30 mg/day for 14 to 16 days. " 07/01/1998 - "pylori infection received lansoprazole 15 mg at bedtime, whereas 46 in whom H. " 03/01/1998 - "pylori infection were randomized to receive lansoprazole 30 mg b.i.d. "

Related Drugs and Biologics

1.	Omeprazole (Prilosec)
2.	Proton Pump Inhibitors
3.	Acids
4.	Amoxicillin (Wymox)
5.	Ranitidine (Zantac)
6.	Clarithromycin (Biaxin)
7.	Esomeprazole (Nexium)
8.	Pantoprazole (Protonix)
9.	Famotidine (Pepcid)
10.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Fundoplication
4.	Secondary Prevention
5.	Mechanical Ventilators (Ventilator)